Information Provided By:
Fly News Breaks for May 13, 2016
TTPH
May 13, 2016 | 08:09 EDT
After Tetraphase announced that it would conduct a second Phase III trial of its cIAI drug, SunTrust thinks that the decision is "appropriate." It cut its price target on the shares to $14 from $21, but it believes that the 24% after hours drop in the shares was overdone, and it "strongly" recommends buying the stock.
News For TTPH From the Last 2 Days
There are no results for your query TTPH